Viral Vector Titre via PKC Activator and HDAC Inhibitor

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The mass production of Good Manufacturing Practice (GMP) grade viral vectors faces challenges due to inefficiencies in titre maximization during the upstream and downstream phases of production, including viral serotype, transgenic sequence composition, media composition, transfection processes, and cell viability issues.

Innovation Solution

The use of a PKC activator, either alone or in combination with a HDAC inhibitor, in the cell culture medium significantly increases viral vector titre by enhancing production and maintaining cell viability, specifically for lentiviral vectors, and can include prostratin or phorbol 12-myristate 13-acetate as PKC activators and sodium butyrate or suberanilohydroxamic acid as HDAC inhibitors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If common methods of viral vector manufacture (transfection of primary cells or cell lines) are used, then viral vector production can be achieved, but titre maximization is limited and production efficiency is insufficient

Engineering Contradiction:

Improveviral vector titreVSAvoidproduction efficiency

Core Design Contradiction:

ProductivityVSEase of manufacture

Solution Approach 1:

The patent applies parameter changes by introducing chemical inducers (PKC activators such as PMA or prostratin, and HDAC inhibitors such as sodium butyrate or TSA) to modify the cellular environment and stimulate enhanced viral vector production. These chemical parameters directly influence gene expression and viral assembly, thereby increasing titre without fundamentally changing the transfection-based manufacturing process.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a composite approach by combining multiple induction agents (PKC activator plus HDAC inhibitor) to achieve synergistic effects on viral vector production. This multi-component induction strategy addresses the limitations of single-agent systems and maximizes titre while maintaining process compatibility with existing manufacturing methods.

Inventive Principle:

Principle #40Composite materials

2Productivity

If producer cell lines with stably integrated vector component expression cassettes are used, then transfection-independent approaches are enabled at larger scales, but cell fragility and viability issues persist

Engineering Contradiction:

Improvelarge-scale production capabilityVSAvoidcell viability

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies preliminary action by pre-inducing producer cell lines with PKC activators and HDAC inhibitors before viral vector harvest. This pre-treatment enhances the cells' production capacity and stabilizes their viability during the induction period, allowing for more robust large-scale production without compromising cell health during the critical production window.

Inventive Principle:

Principle #10Preliminary action

3Productivity

If multiple factors are optimized during upstream phase (viral serotype, transgenic sequence composition, media composition, transfection reagent, chemical induction timing), then viral vector production efficiency can be improved, but process complexity increases

Engineering Contradiction:

Improveviral vector production efficiencyVSAvoidprocess complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent applies universality by developing a multi-functional induction system where PKC activators and HDAC inhibitors simultaneously address multiple production parameters. These chemical inducers affect gene expression, viral assembly, and cell viability across different viral serotypes and transgenic configurations, providing a universal enhancement strategy that reduces the need for separate optimizations of each individual parameter.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach leads to increased viral vector titre and maintained cell viability, effectively addressing the bottlenecks in viral vector production by optimizing production conditions and enhancing vector output.

Implementation Method 1

use of a PKC activator alone or in combination with a HDAC inhibitor during viral vector production significantly increases viral vector titre

Methodology Applied

Scientific EffectPKC activation: Enzyme

Implementation Method 2

use of a PKC activator alone or in combination with a HDAC inhibitor during viral vector production significantly increases viral vector titre

Methodology Applied

Scientific EffectHDAC inhibition: Enzyme

Data Source

PatentUS20230183742A1Viral Vector Production

Publication Date: 2023.06.15 OXFORD BIOMEDICA (UK) LTD

AI summary

The present invention provides novel methods for producing a viral vector. Corresponding viral vector production systems and uses are also provided.